Everest Medicines announced it has entered into a collaboration and license agreement with Kezar Life Sciences ("Kezar"), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, to develop and commercialize Kezar's lead drug candidate zetomipzomib, a novel, first-in-class, selective inhibitor of the immunoproteasome for a range of autoimmune diseases including lupus nephritis (LN), in Greater China, South Korea and some Southeast Asian countries. Under the terms of the agreement, Kezar is entitled to receive an upfront payment of $7 million, and clinical and commercial milestone payments of up to $125.5 million, as well as tiered single-digit to low-teens royalties on net sales of products. Everest will also have the option to localize manufacturing.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
20.25 HKD | +1.35% | -3.34% | -3.11% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
20.25 HKD | +1.35% | -3.34% | 821M | ||
0.7099 USD | +0.20% | +1.70% | 51.68M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.11% | 821M | |
+0.37% | 91.38B | |
-2.37% | 38.68B | |
+71.42% | 27.84B | |
-12.31% | 16.05B | |
-4.54% | 13.48B | |
-10.83% | 11.73B | |
+180.20% | 10.74B | |
-48.60% | 10.39B | |
+1.42% | 8.94B |
- Stock Market
- Equities
- 1952 Stock
- News Everest Medicines Limited
- Everest Medicines Enters into Collaboration and License Agreement with Kear Life Sciences to Develop and Commercialize Zetomipzomib in Greater China and Other Asian Markets